In this interview, Andrew Kates, MD, FACC, and Alison L. Bailey, MD, FACC, discuss the top takeaways in general cardiology from 2023 including ARAMIS, ORBITA-2, and STOP-CA trials.

Related References:

1. Rajkumar, C., Foley, M., Ahmed‐Jushuf, F., Nowbar, A. N., Simader, F., Davies, J. R., O’Kane, P., Haworth, P., Routledge, H., Kotecha, T., Gamma, R., Clesham, G. J., Williams, R., Din, J., Nijjer, S., Curzen, N., Ruparelia, N., Sinha, M., Dungu, J., . . . Al‐Lamee, R. (2023). A Placebo-Controlled Trial of percutaneous coronary intervention for stable angina. The New England Journal of Medicine, 389(25), 2319–2330. https://doi.org/10.1056/nejmoa2310610
2. Neilan, T. G., Quinaglia, T., Onoue, T., Mahmood, S. S., Drobni, Z. D., Gilman, H. K., Smith, A., Heemelaar, J. C., Brahmbhatt, P., Ho, J. S., Sama, S., Svoboda, J., Neuberg, D. S., Abramson, J. S., Hochberg, E. P., Barnes, J. A., Armand, P., Jacobsen, E. D., Jacobson, C. A., Kim, A. I., … Scherrer-Crosbie, M. (2023). Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA, 330(6), 528–536. https://doi.org/10.1001/jama.2023.11887
3. Kerneis, M., Cohen, F., Combes, A., Amoura, Z., Pare, C., Brugier, D., Puymirat, E., Abtan, J., Lattuca, B., Dillinger, J. G., Hauguel-Moreau, M., Silvain, J., Salem, J. E., Gandjbakhch, E., Hekimian, G., Redheuil, A., Vicaut, E., Montalescot, G., & ACTION Study Group (2023). Rationale and design of the ARAMIS trial: Anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis. Archives of cardiovascular diseases, 116(10), 460–466. https://doi.org/10.1016/j.acvd.2023.07.004
4. Nowbar, A. N., Rajkumar, C., Foley, M., Ahmed-Jushuf, F., Howard, J. P., Seligman, H., Petraco, R., Sen, S., Nijjer, S. S., Shun-Shin, M. J., Keeble, T. R., Sohaib, A., Collier, D., McVeigh, P., Harrell, F. E., Francis, D. P., & Al-Lamee, R. K. (2022). A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 17(18), 1490–1497. https://doi.org/10.4244/EIJ-D-21-00649
5. Jain A, Zahra F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Updated 2023 Apr 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574531/